newsfilter
← Earnings
Earnings Releases·

ADARx Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Collaboration revenue rose to $2.2 million from $1.6 million year-over-year, while net loss widened to $28.1 million from $17.9 million due to increased R&D and G&A expenses.
  • The company secured a strong balance sheet with $901.0 million in cash and investments as of September 30, 2026, following a September 2026 IPO and private placement that generated approximately $602.5 million in gross proceeds.
  • Management projects existing capital resources will fund operations and capital requirements through 2030, with key clinical milestones including Phase 2 data for Agazisiran in mid-to-late 2027 and Phase 3 top-line data for Onvuzosiran by year-end 2027.
  • Strategic progress includes the FDA granting Fast Track designation to Onvuzosiran in August 2026, the initiation of Phase 2 planning for ADX-626, and the planned 2027 Phase 1 initiation for preclinical candidates ADX-077 and ADX-199.
Company
ADARX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology